MAb 4 - Zydus CadilaAlternative Names: MAb4
Latest Information Update: 22 Oct 2015
At a glance
- Originator Zydus Cadila
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 21 Oct 2015 Clinical trials in Cancer in India (Parenteral) (Zydus presentation, May 2015)